WIXLIB

Innovation in in R/D policyIdeaPolicyScienceTechnologyVC vatePartnershipsAllianceManagementThe very rich Lundbeck fund is to dedicateEuro 35 M to help Danish researchers tostay in Denmark to research. One ofDenmark’s largest money tanks theLundbeck fund will now attract the bestDanish brains abroad to return home toresearch to be of benefit to Denmark,writes “Berlingske Business”.Alexander Innovation ZoneThessaloniki, Greece

BMF strategy:Innovation in biomapping activityWestern Denmark electronic biomap projectAn innovative mapping project to: accurately map the Western Denmarkbioregion to reveal biocompetencies for thepurpose of attracting foreign investments andestablishing research and business biopartnership to surface hidden know how potential, whichpreviously was not fully recognizedAlexander Innovation ZoneThessaloniki, Greece

Network ViewDatabase ViewGeographical ViewAll BMFAcademiaHealth Biotech& BiomedicalSupportivePlatform- basedView All5 divisionsSelect AreaHospitalsProduct- basedAlexander Innovation ZoneThessaloniki, Greece

Western Denmark rch:Favorites: CbvbbfxNetwork ViewBiotechnologyList View Vcxvfafa XvcvfagfKeywordsPop-upwhen Mouse– over theUNIT ofpossibleinterest BxvhgBiologyEnvironmentcomBvsbd bdbDbbC ABCCBGeneticsBioinSelect: X AllAlexander Innovation Zone Companies Academia/HospitalsThessaloniki, Greece

BMF overall strategy:Aarhus biocluster to gain competitiveadvantage in the global marketTo facilitate partnership between Danish andforeign Biotechs/Pharma for codevelopment andout-licensing of Danish technology/bio-products To help Aarhus companies to gain competitiveadvantage in the fierce world Bio-arena To considerably impact as biocluster in EuropeAlexander Innovation ZoneThessaloniki, Greece

Aarhus biocluster, DenmarkBiotech company categories Selected Drug Discovery Biotech companiesSelected Non-Drug Discovery BiotechcompaniesSelected Medical Technology companiesFood and food-supplement companiesAlexander Innovation ZoneThessaloniki, Greece

Aarhus biocluster, DenmarkSelected Drug Discovery Biotechcompanies (moderate at national level) Action Pharma: Acute myocardial infarction and inflammatory diseases ReceptIcon: Treatment of drug-related adverse effects (organ damage) e.g.renal cancer Cobento: Production of recombinant therapeutic proteins in GMO plants fortreatment of vitamin B12 deficiency, which can lead to dementia and depression Borean Pharma: Trimerization technology platform leading to development of humanprotein drugs of high specificity. Application in a wide spectrum of diseases Cell Cure: Development of patient-specific therapeutic protocols for metastatic Ca Senentek: development of advanced treatments for anti-aging (HQ in California)Alexander Innovation ZoneThessaloniki, Greece

Biotech company: Action PharmaEstablished: 2000, Locations: HQ in Aarhus, office in Copenhagen,Focus: Discovery and development of new drugs and treatment concepts withindiseases associated with ischemia and inflammationKey company information: R&D pipeline with pre-clinical validated targets Company completing clinical development of selected program Orphan drug indication and hence “fast track” regulatoryadvantages Strategic collaborations with two European biotech companies Several bn markets with attractive commercial perspectives Busin. model: out-licensing opportunities supported by strongIPR Acquired total venture capital in excess of 3 M(2000-Innovation2005) fromAlexanderZoneThessaloniki, Greecelocal VCs: Incuba Ventures, Vækstfonden.

Action Pharma (II)(www.actionpharma.com)Dermatitis (include atopic dermatitis and psoriasis), SIRS systemic inflammatory response syndrom; AMI acute myocardialinfarction; ARF acute renal failure; COPD chronic obstructive pulmonary disease (with focus on acute inflammatory excerbations).Alexander Innovation ZoneThessaloniki, Greece

Aarhus biocluster, DenmarkSelected Non-Drug Discovery Biotechcompanies(moderate at national level) Aros Applied Biotechnology: Gene expression analysis by oligonucleotide chips andmicro-array service provider. European pioneer in Affymetrix chip analysis DNA Technology: Custom-made oligonucleotides and molecular diagnostic kits ProteoTarget: Phage display technology focused on malignant cell proliferation Loke Diagnostics: Chlamydia and Mycoplasma molecular diagnostic products andvaccine development Pipeline Biotech: Pharmacological CRO offering pre-clinical and pharmacokineticstudiesAlexander Innovation ZoneThessaloniki, Greece

AROS Applied Biotechnologywww.arosab.comEstablished: 2000, by scientists at the Mol. Diagn. Lab, AUH (University spin out).Key contact: Torben Ørntoft. Employees: 7A leading microarray service provider and CRO for thepharmaceutical industry and the academic community. Aros wasthe first European institution to purchase an Affymetrix system(1999), and went into a business partnership with Affymetrixthat has continued without interruptions ever since. Thus AROS isofficial Service Provider for the complete product line ofAffymetrix's genomic chip platforms.Alexander Innovation ZoneThessaloniki, Greece

Aarhus biocluster, DenmarkSelected Medical Technology companies(strong nationally & competitive in Europe)Development and production of equipment for Vivox: control of temperature & gas composition Curatio: Wound cleaning Danish Myo Technology: Myographs for physiology and pharmacology studies HistOtech: Preservation of the stereology/3D structure of pathological sections Med. Engineering: Pulse measuring and other handheld measurement devicesNRT: X-ray equipment development providing for GE and Philips among others Pysiotech: Physiotherapy and rehabilitation Unisense: Microsensors for environmental & IVF purposesAlexander Innovation ZoneThessaloniki, Greece

Aarhus biocluster, DenmarkFood and food-supplement companies(very strong, internationallycompetitive)Modern biotechnology is an integrated part of the Aarhus foodlarge corporations: Arla, Aarhus United, Compact, Ceres,Danisco and Danish Crown - and SMEs, which possess long trackrecord & experience in: Sugarand sugar-derivates Dairyproducts and derivates Oiland derivates Diverseindustryequipment and machinery with focus on the foodAlexander Innovation ZoneThessaloniki, Greece

UniversityAarhus County& MunicipalityAarhus Food industryAarhus alEngineer.EngineerEUfundingBMFalcidme arkoiBePcnScieInvest: preseed, seed,VCsInvest in DenmarkStart-upbiotech andmed ARKETAlexander Innovation ZoneThessaloniki, Greece

Innovation ZoneEnvironmentimpact onNew bioeconomyAlexander Innovation ZoneThessaloniki, Greece

InnovationZone/environmentAn Innovation Zone/Environment Needs to have access to first class research(first Max Plunk Institute outside Germany) Supports the commercialisation of researchideas Is critical to new technology innovativeSMEs can generate growth for the entire respectiveregionAlexander Innovation ZoneThessaloniki, Greece

Innovative start-ups give birth toNew Economy In any industry over 80% of all start-ups failwithin five yearsWhat are the critical factors for a newtechnology company-usually a spin out froma university-to sustain, become innovativeand achieve commercialization of its patentprotected research discoveries?Alexander Innovation ZoneThessaloniki, Greece

Critical factors for new technologystart-up companies to grow andsustain Breakthrough research results to base yourbusiness plansFollow scientific and technology trendsAccess to key business development personnel(technology valuation, licensing, .)Intellectual Property (patent portofolio)Negotiating Partnership/AllianceManagementInnovation Zone environment/clusterAlexander Innovation ZoneThessaloniki, Greece

Dubai Innovation Zoneworld class cluster and businesshub DuBiotech (Dubai biotechnology park)The Foundation for research and innovationDubai internet cityDubai media cityKnowledge village and academic cityAlexander Innovation ZoneThessaloniki, Greece

Thessaloniki Innovation Zone:Actions Accomplished Completionof legislative framework inaccordance with EU regulations Creation of Alexander Innovation Zone S.A.(AIZ) Operation of A.I.Z started mid summer 2007 Initial funding received early Nov. 2007 after itwas seriously cut from that originally requested.As a result no personnel yet nor company officesrentAlexander Innovation ZoneThessaloniki, Greece

Thessaloniki Innovation Zone area(current situation)RESEARCH INSTITUTES &TECHNOLOGY PARKTECHNOLOGY MUSEUMTHESSALONIKITECHNOPOLISunder constructionLarge private owned land(land reserve forInnovation Zone)(10 ha.- 70 tenants)IT firms3 Business Incubators(35 incubatees)THE SEALarge state owned land(land reservefor Innovation Zone)Alexander Innovation ZoneThessaloniki, Greece

Thessaloniki Innovation ZoneAlexander Innovation Zone S.A.:Actions in progress Strategic Plan for the Thessaloniki Innovation(Under the auspices of Ministry of Macedonia-Thrace)Zone ThessalonikiInnovation Zone land surveys, Spatialplanning, Master Plan (Under the auspices of Ministry of MacedoniaThrace)Large state & private owned plots survey for candidateareas to become part of the Innovation Zone [Sedes old military airport (50 ha), AFS area adjacent to Technopolis, (30 ha), Min. of Agriculture (18 ha)]Incentives for companies to settle within the Zone(preliminary work completed) Alexander Innovation ZoneThessaloniki, Greece

Plan for a Biotech clusterwithinthe Thessaloniki InnovationZone areaAlexander Innovation ZoneThessaloniki, Greece

1. Institute of Biomedical andBiomolecular Research (IBBR)The Institute of Biomedical and BiomolecularResearch(IBBR) was created in 2007. IBBR goals are in thesupportof biomedical research based on a multidisciplinaryapproach amongst various scientific thematic areas in: Biomedical informatics, Biomedical engineering, Molecular medicine, and. on ZoneThessaloniki, Greece

1. Institute of Biomedical andBiomolecular Research (IBBR)The Institute aims in supporting researchdevelopmentin the basic as well as applied biomedical area. Thedevelopment, assessment and standardization ofinnovative research as well as spin-off biotech andbiomedical engineering companies for the supportand uptake of innovative applications, services andproducts aimed at medical practice with emphasis ondisease prevention and non-invasive treatment ofdiseasesAlexander Innovation ZoneThessaloniki, Greece

2. Economou-KoskinasBrain & Intelligence Institute,Thes/nikiSectors and Divisions Basic Neurosciences Structural and Functional NeuroscienceBehavioral and Cognitive NeuroscienceApplied Neurosciences Decisions and Policy MakingMind and CreativitySpecial Education ApplicationsAlexander Innovation ZoneThessaloniki, Greece

Atlas of Cytoarchitectonics of the Adult Human Cerebral CortexEconomo C von, Koskinas GN, Triarhou LC (2008) Karger, Basel, p. 171What we group under the name of the sciencesis, as the application of the word in the pluralshows, no single entity, but consists of manyseparate fields of knowledge, which often lie farapart. Through the increase of such knowledge,these fields increase, and their boundaries,originally far apart, approach each other moreand more. The investigation of these borderzones then becomes one of the most interestingproblems in science and a new branch ofscience itself, whereby the experience andmethods of one speciality are applied to theother and entirely new points of view arereached that lead to fruitful work in both fields.– Constantin von Economo * (1931)Alexander Innovation ZoneThessaloniki, Greece

3. Investing in biomarkertechnologyThe use of biomarkers in BioPharma R&D and diagnosticswill enable more precise, predictive and preventive clinicalcare. Biomarker-enabled R&D is evolving into a newdiscipline with a strong patient focus. Many organizationsthat believe in biomarker enabled R&D, are investing inbiomarker technology. Many leading companies, such asNovartis, Eli Lilly, Bristol-Myers Squibb, Pfizer and Bayer,have developed new R&D processes based on theuse of biomarkers throughout the clinical trials process forcardiology, oncology and neurology.IBM Global Business ServicesAlexander Innovation ZoneThessaloniki, Greece

3a. Biomarkers & Imaging fieldIn the imaging field, biomarkers are increasingly beingused non-invasively to assess patients’ localized disease progression and response to drug candidatesBiomarkers can help determine whether the drug reaches the target, it affects biological activity, and, if it does, whether that effect leads to thedesired clinical outcomeIBM Global Business ServicesAlexander Innovation ZoneThessaloniki, Greece

3b. Biomarkers in clinical trialsInnovative strategies are needed for biomarkerdiscovery and validation that parallel theapproach to therapeutics. A collaborativeapproach to biomarker discovery usingstandardized tissue and biological fluidspecimens, ideally collected as part of clinicaltrials, has the potential to Fasttrack biomarkerdiscoveryAlexander Innovation ZoneThessaloniki, Greece

3c. Biomarkers pave the way forInformation-Based MedicineBiomarkers are becoming a foundation for informationbased medicine in determining who should be treated,how and with what. For biomarkers to reach their fullpotential, alone or in combination, they must undergotheir own development process. Biomarker developmenthas lagged significantly behind therapeutic developmentbecause of scientific, economic and regulatory factors. Itis important to accelerate biomarker development and tohelp biomarkers advance in parallel with therapeutics,but, they must be tested with established therapiesIBM Global Business ServicesAlexander Innovation ZoneThessaloniki, Greece

3d. Biomarkers Value forthe biotech companiesBiomarkers provide increasing value as companiesmove along the path from drug discovery to productlaunch because: Costs go up at each progressive stage. More knowledge is needed to reduce risks atprogressive stages. Regulatory “proof” requires more rigor as oneapproaches approval “stage-gates.” Technique and technology must be “locked down”through the multiyear clinical phasesIBM Global Business ServicesAlexander Innovation ZoneThessaloniki, Greece

3e. Biomarker Consortium: Innovationin PPP NIH approach to speed upclinical useThe Biomarker Consortium is a program sponsored by the Foundationfor the National Institutes of Health to bring private and publicpartners together to support the NIH vision. Its strategy is to create“harmonized approaches” to speed up biomarker value and formal useto promote research, regulatory approval, and more informed decisions.The Consortium carefully develops policies to address IP concerns,data sharing, antitrust issues, grantee/contractor selection,confidentiality and conflicts of interest. Currently, the BiomarkerConsortium is focusing on three projects: Neuroscience: Major Depressive Disorder – identifying its genomicbiomarkers Metabolic diseases: Such as diabetes Oncology: FDG-PET for lung cancer and lymphomaIBM Global Business ServicesAlexander Innovation ZoneThessaloniki, Greece

4. Outsourcing biomanufacturing inthe Thessaloniki Innovation ZoneBiotech companies will rely upon an outsourced businessmodel like the 60% of pharma industry. This is true forbioregions as well. A region doesn’t have to build itself upasanother San Diego. For instance a company in Seattle canhave manufacturing in Carolina, marketing offices inNewJersey, and clinical trial in Kansas. Regions with specificstrengths in this outsourced business model will beAlexander Innovation Zoneinterconnected with each otherThessaloniki, Greece

Roche Holding AG to Invest about 400M to Expand Biotech Operations 1/18/2008ZURICH (MarketWatch) -- Roche HoldingAG Friday said it plans to invest 391 millionto expand biotech drug research,development and production at sites inSwitzerland and Germany.Alexander Innovation ZoneThessaloniki, Greece

Meet one-on-one with investors, analysts, invest.bankers and potential corporate partners Hear panel discussions and keynotes by veteran investment and company executives Network with peers, investors and potential partners attending the conference Get the pulse on the current and proposed investment trends in biotechnology Why Investors Attend: